Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.

Sponsor
Amsterdam UMC, location VUmc
Study ID
NCT01636908
Status
Completed

Conditions

  • Advanced Solid Tumors
  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Sunitinib — DRUG
    50 mg once daily, oral use, 14 days
  • Sorafenib — DRUG
    400 mg, twice daily, oral use, 14 days
  • Erlotinib — DRUG
    150 mg once daily, oral use, 14 days
  • Everolimus — DRUG
    10 mg once daily, oral use, 14 days
  • Lapatinib — DRUG
    1250 mg once daily, oral use, 14 days
  • Dasatinib — DRUG
    100 mg once daily, oral use, 14 days
  • Pazopanib — DRUG
    800 mg once daily, oral use, 14 days
  • Vemurafenib — DRUG
    960 mg twice daily, oral use, 15-21 days
  • tumor biopsy — PROCEDURE
  • skin biopsy (optional) — PROCEDURE

Study Details

The purpose of this study is to determine intratumoral concentration of kinase inhibitors upon 2 weeks of treatment in tumor tissue of patients.

Key Dates

Start date
Aug 31, 2011
Status verified
Apr 2021
Primary completion
Jan 1, 2018
Completion
Dec 1, 2019

Study Design

Enrollment
43 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Kinase inhibitor
    Patients are cohort-wise treated with a registered (tyrosine) kinase inhibitor

Primary Outcome Measure

concentrations of intratumoral kinase inhibitors upon 2 weeks of treatment [ Time Frame: 2 weeks ]

Related Studies